ContributorsPublishersAdvertisers

Biology

MedicalXpress

Fourth-generation vaping devices increase risk to immune cells

Not all electronic cigarette devices are created equal. Some fourth-generation models—such as Juul devices—are associated with unique changes in markers of immune responses inside our airways, according to a new paper from UNC School of Medicine researchers led by toxicologist Ilona Jaspers, Ph.D., director of the UNC Center for Environmental Medicine, Asthma, and Lung Biology and director of the UNC Curriculum in Toxicology and Environmental Medicine.
CANCER
Picture for Fourth-generation vaping devices increase risk to immune cells

Symrise Partners With Biotech Company to Advance Beauty Ingredients

PARIS — Symrise Cosmetic Ingredients has partnered with Evoxx, a biotech company, to develop biotechnological processes for beauty ingredients. “Evoxx contributes its expertise in research and development, as well as its global leadership in manufacturing of enzymes and probiotics,” Symrise, the Holzminden, Germany-based fragrance and flavors supplier, said in a statement released Thursday. “Symrise adds their knowledge and capabilities in creating innovative and sustainable cosmetics ingredients.”
MEDICAL & BIOTECH
Picture for Symrise Partners With Biotech Company to Advance Beauty Ingredients
RELATED PEOPLE
RELATED PUBLISHERS
Motley Fool

3 Things About Moderna That Smart Investors Know

COVID-related revenue will decrease but won't go away entirely. Moderna has dozens of products in development, including a few in phase 3 trials. Investors shouldn't assume the cheap valuation means an investment is without risk. You’re reading a free article with opinions that may differ from The Motley Fool’s Premium...
MEDICAL & BIOTECH
Motley Fool

Why Pfizer Popped While the Market Flopped Today

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More. What happened. Thursday was generally a lousy day...
STOCKS
YOU MAY ALSO LIKE
technologynetworks.com

Advancing Synthetic Biology With Automation

Biology is messy. For scientists, that’s part of its challenge—and its beauty. Synthetic biologists, however, aren’t just studying life. Instead, the field of synthetic biology is transforming cells into molecular factories that can make everything from food and fuel to pharmaceuticals and agriculture. The natural complexity and stochasticity of living systems makes this a complex task. To reprogram a cell requires more than just the right genes, it requires precisely balancing the timing and expression of each gene so reactions proceed in the right order and at the right time. Doing this requires accurate and precise editing methods and rounds and rounds of tuning.
MEDICAL & BIOTECH

Heron Therapeutics to cut about one-third of its workforce as part of cost-cutting plan

Heron Therapeutics Inc. HRTX, -12.30% said Thursday it will lay off about one-third of its workforce as part of a restructuring expected to save $43 million a year. The biotechnology company's stock was still inactive in premarket trading. The company said it's enacting the restructuring and cost cutting measures to address "the current market realities and macro headwinds facing many commercial-stage biotechnology companies," and to help support its acute care and oncology care franchises. The company said the cost cutting actions will mostly result from the reduction of 34% of its workforce, which would represent about 103 employees, based on 302 full-time employees the company had as of Dec. 31. Heron said about 70% of the jobs being cut are coming from research and development. The stock has plunged 65.3% year to date, while the iShares Biotechnology ETF.
MEDICAL & BIOTECH